Brokerages expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post earnings per share (EPS) of ($1.82) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.95) and the highest is ($1.67). Alnylam Pharmaceuticals reported earnings per share of ($1.06) in the same quarter last year, which indicates a negative year-over-year growth rate of 71.7%. The company is expected to issue its next earnings report on Tuesday, November 6th.

On average, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($6.65) per share for the current fiscal year, with EPS estimates ranging from ($6.96) to ($6.23). For the next fiscal year, analysts forecast that the firm will report earnings of ($7.02) per share, with EPS estimates ranging from ($8.74) to ($5.88). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.11. The company had revenue of $29.91 million for the quarter, compared to analysts’ expectations of $16.96 million. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. Alnylam Pharmaceuticals’s quarterly revenue was up 87.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.07) EPS.

A number of equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday. BidaskClub cut shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $117.00 target price (down from $123.00) on shares of Alnylam Pharmaceuticals in a report on Thursday. Finally, Piper Jaffray Companies dropped their target price on shares of Alnylam Pharmaceuticals from $182.00 to $160.00 and set an “overweight” rating on the stock in a report on Wednesday, June 27th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $145.55.

In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the transaction, the chief operating officer now directly owns 1,916 shares of the company’s stock, valued at approximately $229,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction dated Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total transaction of $5,269,500.00. Following the completion of the transaction, the chief executive officer now directly owns 201,297 shares in the company, valued at $21,214,690.83. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,063 shares of company stock worth $5,733,678. Insiders own 4.30% of the company’s stock.

Large investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. grew its position in shares of Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 268,111 shares of the biopharmaceutical company’s stock worth $26,406,000 after purchasing an additional 20,357 shares in the last quarter. Amalgamated Bank grew its position in shares of Alnylam Pharmaceuticals by 11.3% during the 2nd quarter. Amalgamated Bank now owns 20,420 shares of the biopharmaceutical company’s stock worth $2,011,000 after purchasing an additional 2,080 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 5.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 277,352 shares of the biopharmaceutical company’s stock worth $33,033,000 after purchasing an additional 14,936 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 410.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 7,650 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 6,150 shares in the last quarter. Finally, Riverhead Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares in the last quarter. Hedge funds and other institutional investors own 93.36% of the company’s stock.

Shares of ALNY stock traded up $2.18 on Thursday, reaching $97.14. The stock had a trading volume of 802,411 shares, compared to its average volume of 999,319. The company has a quick ratio of 13.22, a current ratio of 13.22 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 12 month low of $74.50 and a 12 month high of $153.99.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Further Reading: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.